| Date Filed | Type | Description |
| 10/05/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/29/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/27/2023 |
8-K
| Other Events Interactive Data |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/28/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Miami, FL – May 12, 2023 – Avenue Therapeutics, Inc. , a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023. “Avenue is progressing its neuro-focused clinical stage pipeline and 2023 is off to a strong start with AJ201, a first in class small molecule for the treatment of Spinal and Bulbar Muscular Atrophy , now in an ongoing Phase 1b/2a clinical trial, and BAER-101, a potentially more tolerable drug for the treatment of epilepsy and acute anxiety, advancing toward Phase 1b studies in each indication. We..." |
|
| 05/04/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/08/2023 |
8-K
| Appointed a new director |
| 03/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 02/14/2023 |
SC 13G/A
| CVI Investments, Inc. reports a |
| 02/14/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/25/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 01/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/06/2023 |
SC 13D/A
| Fortress Biotech, Inc. reports a 11.3% stake in AVENUE THERAPEUTICS, INC. |
| 01/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/04/2023 |
SC 13G
| SABBY MANAGEMENT, LLC reports a 5.5% stake in Avenue Therapeutics, Inc. |
| 12/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/18/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/18/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|